★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
◀ BACK TO FEED
NEWS★ LIFE SCIENCES / BIOTECHNOV 10, 2026

Oyster raises $60m to advance brain-targeted protein degraders

A promising drug mechanism still needs to reach the part of the body where it is needed.

Oyster raises $60m to advance brain-targeted protein degraders

A promising drug mechanism still needs to reach the part of the body where it is needed.

What happened

Oyster Therapeutics, formerly Kesmalea, announced a $60m Series A-2 led by 4BIO Capital, with participants including Eli Lilly. Funding supports development of an oral, brain-penetrant drug designed to remove disease-associated tau protein, alongside its protein-degradation platform.

Why it matters

Reaching the brain is a major challenge in drug development. Oyster is targeting that problem in diseases associated with abnormal tau, including Alzheimer's.

The bigger picture

The financing supports development towards clinical testing. Evidence from that programme will determine whether the approach can become a useful treatment.